June 26, 2021 –  “Johnson & Johnson helped fuel this fire, but today they’re committing to leaving the opioid business — not only in New York, but across the entire country,” she said. “Opioids will no longer be manufactured or sold in the United States by J&J.”

The New York opioid lawsuit trial against the rest of the defendants will begin this week, according to the release. Other defendants in the New York suit include Purdue Pharma; Mallinckrodt LLC; Endo Health Solutions; Teva Pharmaceuticals USA; and Allergan Finance LLC.

In a statement Saturday, Johnson & Johnson said the settlement “is not an admission of liability or wrongdoing by the company” and is “consistent with the terms of the previously announced $5 billion all-in settlement agreement in principle for the resolution of opioid lawsuits and claims by states, cities, counties and tribal governments.”

The company also said it would continue to defend against any lawsuits the final agreement does not resolve.

James said the state will focus on funding for opioid prevention, treatment and education efforts in order to “prevent any future devastation.”


[ninja-popup ID=12216]